Featured Jobs
|
Relationship Manager for Defined Benefit/Cash Balance Plans Daybright Financial
|
|
Managing Director - Operations, Benefits Daybright Financial
|
|
BPAS
|
|
MAP Retirement
|
|
Retirement Plan Administration Consultant Blue Ridge Associates
|
|
Anchor 3(16) Fiduciary Solutions
|
|
ESOP Administration Consultant Blue Ridge Associates
|
|
Cash Balance/ Defined Benefit Plan Administrator Steidle Pension Solutions, LLC
|
|
Pentegra
|
|
Regional Vice President, Sales MAP Retirement USA LLC
|
|
Retirement Plan Consultants
|
|
BPAS
|
|
Retirement Relationship Manager MAP Retirement
|
|
Southern Pension Services
|
|
July Business Services
|
|
BPAS
|
Free Newsletters
“BenefitsLink continues to be the most valuable resource we have at the firm.”
-- An attorney subscriber
|
|
|
The Future of Metabolic Health and Weight Loss Drugs: Projecting Mortality Reductions
Swiss Re Group 
Sept. 22, 2025 "Widespread use of GLP-1 weight loss drugs to treat obesity could reduce cumulative all-cause mortality by up to 6.4% in the US and 5.1% in the UK general populations by 2045 ... GLP-1 drugs may reshape claims experience across mortality, longevity and medical insurance products.... In the US and UK general populations, [the] modelled baseline scenario projects 4% and 3.2% reductions in cumulative all-cause mortality respectively by 2045, based on GLP-1 drug use." MORE >> |
| Please click here to report this link if it is broken (for example, if you see a "404 File Not Found" error message after you click on the linked news item's title). |
| An important word about authorship: BenefitsLink® created this link to the news item, but we are not the news item's author (unless expressly shown above). |